Goetzl L, Krantz 0, Simpson JL, et al: Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 104(1):30,o2004
Grati FR, Malvestiti F, Ferreira JC, et al: Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med 16(8):620,o2014
Greene MF, Haddow JE, Palomaki GE, et al: Maternal serum alpha-fetoprotein levels in diabetic pregnancies. Lancet 2(8606):345, 1988
Grewal SS, Kahn JP, MacMillan ML, et al: Successful hematopoietic stem cell transplantation for Fanconi anemia from an unafected HLA-genorypeidentical sibling selected using preimplantation genetic diagnosis. Blood 103(3):o1147,o2004
Harper LM, Cahill AG, Smith K, et al: Efect of maternal obesity on the risk of fetal loss after amniocentesis and chorionic villus sampling. Obstet Gynecol 119(4):745,o2012
Hendrickson Be, Donohoe C, Akmaev VR, et al: Diferences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet 46(9):641,o2009
Holmes LB: Report of National Institute of Child Health and Human Development Workshop on Chorionic Villus Sampling and Limb and Other Defects, October 20,o1992. Teratology 48(4):7,o1993
Hook EB, Cross PK, Schreinemachers OM: Chromosomal abnormality rates at amniocentesis and in live-bon infants. JAMA 249(15):2034, 1983
Hsieh FJ, Shyu MK, Sheu Be, et al: Limb defects after chorionic villus sampling. Obstet Gynecol 85(1):84, 1995
Hussamy DJ, Herrera CL, Twickler DM, et l: How many risk factors do Down syndrome pregnancies have? Am J Obstet Gynecol 216(1):S 127, 2017
Huttly W, Rudnicka A, Wald NJ: Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 24(10):804, 2004
Jellife-Pawlowski LL, Baer R, Blumenfeld j, et al: laternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth. BJOG 122(11):1484,o2015
Kaback M, Lim-Steele J, Dabholkar 0, et al: Tay Sachs disease: carrier screening, prenatal diagnosis, and the molecular era. JAMA 270:2307, 1993
Kazerouni NN, Currier RJ, Flessel M, et al: Detection rate of quadruplemarker screening determined by clinical follow-up and registry data in the statewide California program, July 2007 to February 2009. Prenat Diagn 31(9):901,o2011
Knight GK, Palomaki GE: Maternal serum alpha-fetoprotein and the detection of open neural tube defects. In Elias S, Simpson JL (eds): Maternal Serum Screening. New York, Churchill Livingstone, 1992